Biotechnology

Promising Efficacy of AT101 CAR-T for Blood Cancer

SEOUL, South Korea, April 17, 2023 /PRNewswire/ -- AbClon, a South Korean biotech firm, presented non-clinical and phase 1 interim results of its AT101 novel CAR-T therapy at the annual 2023 AACR conference. AT101 targets the CD19 protein for treatment of blood cancer. AT101 demonstrated superio...

2023-04-18 02:00 1662

Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-17 08:20 3104

Introducing the MetaSight® G200: A Revolutionary Third-Generation Chromosomal Karyotyping System Transforming Global Chromosomal Analysis

CHANGSHA, China, April 15, 2023 /PRNewswire/ -- The MetaSight® G200 is a groundbreaking karyotyping system based on high-resolution microscopy technology, capable of accurately detecting chromosomal abnormalities in humans. This innovative system aids doctors in diagnosing and treating diseases ...

2023-04-15 14:43 3112

Minghui Pharmaceutical Inc. Announces Phase 2 Clinical Trial Success of MH004 Cream as a Potential Best-in-Class Topical Treatment for Mild-to-Moderate Atopic Dermatitis and the FDA Clearance of its Global Phase 3 MRCT

* Study met both primary and all key secondary endpoints * Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score was -78.7% in 1.0% MH004 Cream-treated group compared to -46.7% in vehicle group * 79.6% individuals treated with 1.0% MH004 Cream achieved EASI-75 c...

2023-04-14 19:00 6480

Zenshine Pharmaceuticals' ZX-7101A Met the Primary Endpoint of the Phase 2 Study for the Treatment of Acute Uncomplicated Influenza in Adults

NANJING, China, April 13, 2023 /PRNewswire/ -- On April 1st, 2023, during the First Infection Collaboration Forum of the Chinese National Center for Infectious Diseases, Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine Pharmaceuticals) announced that its proprietary anti-influenza agent ZX-71...

2023-04-14 01:15 1971

Viva Biotech Attended SAPA-China

HONG KONG, April 12, 2023 /PRNewswire/ -- 6th-7th April, the "2022 SAPA-China Annual Conference - Opportunities and Challenges for the Development ofChina's Biopharmaceutical Industry" hosted by The Sino-American Pharmaceutical Professionals Association (SAPA) was held inChengdu, Sichuan. Viva Bi...

2023-04-13 11:33 2242

Bridge Biotherapeutics Announces First Patient Dosed in its Phase 2a Clinical Trial of BBT-877, a Potent Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis

SEONGNAM, South Korea and CAMBRIDGE, Mass., April 12, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis, cancer, and inflammation, announced it has dosed the first patient in its Phase 2a clinical study...

2023-04-13 06:00 1849

Standigm announces Younsung Choo as chief executive officer

Former LG life Sciences exec and long-time Standigm advisor brings extensive experience in pharmaceuticals and project management SEOUL, South Korea, April 12, 2023 /PRNewswire/ -- Standigm , a company using artificial intelligence (AI) technology for drug discover...

2023-04-13 00:07 2053

CHITOSE Group Obtains Funding from Japanese Government-affiliated NEDO for Green Innovation Fund of USD400M Range

KAWASAKI, Japan and SINGAPORE, April 12, 2023 /PRNewswire/ -- Chitose Laboratory Corp., the core company of the CHITOSE Group (hereinafter "CHITOSE"), has won funding from a Japanese government-affiliated entity for a project on the self-proposed theme of "Building a global industry originating ...

2023-04-12 14:17 1888

GC Genome-KAIST team Announces Publication of a Groundbreaking AI-Based Liquid Biopsy Technology for Multi-Cancer Early Detection and Localization in Nature Communications

YONGIN, South Korea, April 11, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, today announced the publication of a new study inNature Communications, showcasing the company's novel AI-based liquid biopsy technology. The study highlights the unprecedented accura...

2023-04-12 11:06 1737

Lunit Demonstrates Progress in the Development of Novel Diagnostics at the 2023 AACR Annual Meeting

* Lunit and collaborators demonstrate key progress in the development of novel diagnostics for cancer therapies, including immuno-oncology, in addition to molecular targeted agents and antibody-drug conjugates * Presentations to deliver new research using Lunit SCOPE in a wide range of cancer...

2023-04-11 21:00 1992

Origin Agritech GMO Corn Hybrid is the One and Only Triple Stack Trait Corn Selected for National Demo Plot, Being Grown There in Anticipation of 2023 Commercial Launch

BEIJING, April 11, 2023 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), announced today that its GMO corn hybrid is the one and only triple stacked trait corn selected for the national demo plot and is currently being grown there in anticipation of a 2023 commerci...

2023-04-11 20:45 1850

OnCusp Therapeutics Showcases Potent Anti-Tumor Activity of its CDH6 ADC at AACR Annual Meeting 2023

NEW YORK, April 11, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced that the preclinical data on its lead program CUSP0...

2023-04-11 20:00 1456

Asieris' subsidiary makes significant progress in its commercialization strategy by obtaining the "Drug Distribution License"

SHANGHAI, April 10, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its subsidiary, Hainan Yahong ph...

2023-04-10 20:18 2120

GC Genome Announces Publication Demonstrating Feasibility of Liquid Biopsy Technology to Predict Radiation Therapy Response in Solid Tumors

YONGIN, South Korea, April 9, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a new study in Radiation Oncology Journal,which demonstrates the feasibility of cell-free DNA(cfDNA) monitoring to predict treatment response and detect min...

2023-04-10 11:39 1584

China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released

SHANGHAI, April 6, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the whole industry chain layout, announced its Nectin-4 targeted site-specific ADC asset (R&D code: 9MW2821) demonstrated promising clinical data. The preliminary data show positive therapeut...

2023-04-07 16:34 4368

Nuance Pharma Announces Dosing of First Patient in ENHANCE - China Phase III Trial for Chronic Obstructive Pulmonary Disease ("COPD")

SHANGHAI, April 6, 2023 /PRNewswire/ -- Nuance Pharma ("the Company") announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel solution Ensifentrine in mainlandChina. Ensifentrine is a fi...

2023-04-07 10:00 2150

AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering

NEW YORK, April 6, 2023 /PRNewswire/-- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platfo...

2023-04-07 07:15 4463

GC Cell Obtains Anti-bribery Management System Certification

* Obtained ISO 37001 from Korea Compliance Initiative (KCI) * To practice ESG management by enhancing management transparency and ethical management YONGIN, South Korea, April 6, 2023 /PRNewswire/ -- GC Cell (KOSDAQ: 144510), a Korean biotech company, announced onApr. 6th that it has successf...

2023-04-06 18:03 2062

Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio

CAMBRIDGE, Mass., April 5, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of integrated solutions from "Idea to IND" (I to I™ ), announced today it has entered into a collaboration agreement wi...

2023-04-06 10:20 2375
1 ... 52535455565758 ... 127